Related Experiment Videos
Moderate hypothermia therapy for patients with severe head injury
1Department of Neurosurgery, Chengdu General Hospital of Chengdu Military Command, Chengdu 610083, China.
Objective:
To evaluate the effect and safety of early moderate hypothermia therapy (MHT) on patients with head injury by using parallel-control test.
Methods:
Thirty patients with severe head injury within 6 hours after accidents were treated by MHT generally for 4-10 days. The other 30 patients with similar head injury treated routinely were enrolled for a parallel-control test. The mortality, morbidity and changes of some neuro-functional indexes as Glasgow Coma Scores, and Glasgow Outcome Scale, levels of endothelin and some other factors of neurobiochemistry in blood plasma were observed. Meanwhile, the dynamic monitoring by transcranial Doppler ultrasonography was conducted in these patients.
Results:
The mortality in MHT group was significantly lower than that in control group. MHT not only reduced endothelin but also increased the brain biochemical factors, which were helpful to the protection of neurons in the early brain ischemia after head injury.
Conclusions:
Early MHT can help reduce mortality and morbidity in patients with acute head injury.
Insights
Early moderate hypothermia therapy (MHT) significantly reduces mortality and morbidity in patients with severe head injury. This neuroprotective strategy aids recovery by modulating biochemical factors and improving neurological outcomes.
Area of Science:
- Neurology
- Critical Care Medicine
- Trauma Surgery
Background:
- Severe head injury presents a significant clinical challenge with high mortality and morbidity rates.
- Early intervention strategies are crucial for improving patient outcomes following traumatic brain injury.
Purpose of the Study:
- To evaluate the efficacy and safety of early moderate hypothermia therapy (MHT) in patients with severe head injury.
- To compare outcomes between patients treated with MHT and those receiving routine care using a parallel-control design.
Main Methods:
- A parallel-control study involving 60 patients with severe head injury, treated within 6 hours of trauma.
- MHT was administered for 4-10 days to the treatment group, while the control group received standard care.
- Neuro-functional indexes (Glasgow Coma Score, Glasgow Outcome Scale), biochemical markers (endothelin), and transcranial Doppler ultrasonography were monitored.
Main Results:
- The MHT group exhibited significantly lower mortality rates compared to the control group.
- MHT effectively reduced endothelin levels and increased beneficial neurobiochemical factors.
- These changes suggest a neuroprotective effect, mitigating early brain ischemia.
Conclusions:
- Early application of moderate hypothermia therapy is a safe and effective strategy for reducing mortality and morbidity in acute head injury patients.
- MHT demonstrates neuroprotective benefits in the context of early brain ischemia following traumatic brain injury.